Condition category
Circulatory System
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Cardiovascular diseases (CVD), including heart disease, heart attack and stroke, are a major cause of suffering and disability in many patients. Therefore, there is an urgent need for treatment strategies to prevent CVD, especially in healthy individuals at high risk for CVD. Decades of research have shown that CVD results from multiple risk factors, including smoking, high blood cholesterol, high blood pressure, obesity, chronic stress and depression. Treatment strategies for single risk factors are available, but, until now, only very few studies have targeted all of the aforementioned risk factors at the same time in a larger sample of healthy individuals at high risk for CVD. This study aims to fill this gap. The aim of this study is to find out whether the PreFord intervention reduces the risk of CVD.

Who can participate?
Adults with no evidence of existing CVD, but at high risk for CVD in the future

What does the study involve?
Participants are randomly allocated to either the PreFord intervention or routine care by their GPs. The PreFord intervention consists of 75 hours (total), divided into 30 sessions (2.5 hours each), two times a week, over a period of 15 weeks. It includes health education (e.g., the heart and vessels, healthy food, heart medication, etc), exercise, a smoking cessation programme if necessary, and LifeSkills, an approach to enhance stress resilience and social relationships at work and leisure time. The intervention is accompanied by a guideline-based drug treatment for high blood cholesterol and high blood pressure, if necessary. Well being, health behaviour and CVD risk factors are assessed before and after the intervention, and annually for 5 years. The intervention and each follow-up assessment are free of charge, and participants are free to join or leave the study whenever they wish.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
German Sports University Cologne

When is the study starting and how long is it expected to run for?
August 2004 to July 2013

Who is funding the study?
Bayer Vital (Germany), Pronova BKK (Germany) and AstraZeneca (Germany)

Who is the main contact?
Prof. Hans-Georg Predel

Trial website

Contact information



Primary contact

Prof Hans-Georg Predel


Contact details

German Sports University Cologne
Cologne (Koeln)

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Multimodal intervention for prímary prevention of cardiovascular disease in current and former employees of the Ford motor company, Germany - the PreFord trial



Study hypothesis

A multimodal intervention for primary prevention of cardiovascular disease (CVD) will reduce multiple biological and psychosocial cardiac risk factors and cardiac events.

Re-evaluation of cardiovascular risk and cardiac events annually up to 5 years.

Ethics approval

1. North Rhine Medical Association (Aerztekammer North Rhine) Ethics Committee, 20/12/2004, ref: 2004079
2. Faculty of Medicine Ethics Committee, University of Cologne, 02/02/2004, ref: 03-217

Study design

Two-armed randomized controlled clinical trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Prevention of cardiovascular disease


Multimodal intervention for outpatients, two sessions a week in the afternoon for three months (75 hours total):
1. Health education
2. Exercise therapy
3. Smoking cessation programme
4. Stress management (LifeSkills)

Intervention type



Not Applicable

Drug names

Primary outcome measure

European Society of Cardiology risk score

Secondary outcome measures

1. Health behaviour (physical fitness, smoking, BMI)
2. CVD risk factors, e.g. low-density-lipoprotein cholesterol (LDL-C), total cholesterol, trigycerides, blood pressure, diabetes mellitus, depression and anxiety (HADS), Type-D pattern (DS-14)

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Adult men and women with no evidence for CVD and elevated risk according to the (European Society of Cardiology) ESC risk score > 5%
2. Informed consent

Participant type


Age group




Target number of participants


Participant exclusion criteria

Severe somatic or psychiatric morbidity, e.g. malignancies, psychosis, drug addiction

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

German Sports University Cologne
Cologne (Koeln)

Sponsor information


German Sports University (Germany)

Sponsor details

c/o Prof Dr HG Predel

Sponsor type




Funder type


Funder name

Bayer Vital (Germany)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Funder name

Pronova BKK (Germany)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Funder name

AstraZeneca (Germany)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2004 results in:
2011 results in: Albus C, Bjarnason-Wehrens B, Gysan DB et al. Psychosom Med 2011;73: A-48
2011 results in:
2017 results in:

Publication citations

  1. Results

    Gysan DB, Latsch J, Bjarnason-Wehrens B, Albus C, Falkowski G, Herold G, Mey E, Heinzler R, Montiel G, Schneider CA, Stützer H, Türk S, Weisbrod M, Predel HG, [The PreFord Study. A prospective cohort study to evaluate the risk of a cardiovascular event (overall-collective) as well as a prospective, randomized, controlled, multicentre clinical intervention study (high-risk-collective) on primary prevention of cardiovascular diseases in the Ford Motor Company employees in Germany]., Z Kardiol, 2004, 93, 2, 131-136, doi: 10.1007/s00392-004-0990-3.

  2. Results

    Albus C, Bjarnson-Wehrens B, Gysan DB, Herold G, Schneider CA, zu Eulenburg C, Predel HG, , [The effects of multimodal intervention for the primary prevention of cardiovascular diseases on depression, anxiety, and Type-D pattern: initial results of the randomized controlled PreFord trial]., Herz, 2012, 37, 1, 59-62, doi: 10.1007/s00059-011-3542-4.

Additional files

Editorial Notes

12/07/2017: Publication reference added. 19/02/2016: Plain English summary added.